Listed Companies Have Less Than Six Years to Align With 1.5°C Warming Target, Inaugural MSCI Net-Zero Tracker Reveals
12.7.2021 17:12:00 EEST | Business Wire | Press release
The world’s publicly listed companies must dramatically accelerate climate action if the 1.5°C warming target set out in the 2015 Paris Agreement is to be met, according to a new quarterly Net-Zero Tracker published by MSCI, a leading provider of critical decision support tools and services for the global investment community.
The inaugural Net-Zero Tracker highlights how the annual emissions of listed companies globally are still at the same level as 2013, despite concerted efforts to place climate change at the top of the global agenda. This includes the 2015 Paris Agreement which set a goal to limit global warming to below 2°C, with 1.5°C the preferred target.
Specifically, the MSCI Net-Zero Tracker highlights that listed companies:
- Collectively emit 10.9 gigatons* of direct greenhouse gases every year, as of May 31, 2021
- Need to stay within the remaining emissions budget of 61.4 gigatons of carbon-dioxide equivalent (CO2e) to avoid breaching the 1.5°C threshold
- Would deplete the remaining emissions budget in less than six years, without any change to their current emissions
Henry Fernandez, Chairman and Chief Executive Officer, MSCI, comments: “For the net-zero revolution to be successful it is critical for investors, companies, financial intermediaries and policymakers to come together to divert the world onto a path towards a sustainable future. Despite the rhetoric since the 2015 Paris Agreement, more immediate action is needed. The MSCI Net-Zero Tracker is a progress report for whether the world can keep the global temperature rise below 1.5°C. Listed companies and other capital market participants have less than six years to meet that target.
“In addition to listed companies taking action to drive the transition to net-zero, there needs to be a reallocation of capital by asset owners and an effective channelling of funds by asset managers and banks. This will help reduce the risks of climate change for the world as we all play our part to avert a climate catastrophe.”
The MSCI Net-Zero Tracker provides a quarterly gauge of climate change progress across a global universe of 9,300 publicly listed companies based on the MSCI All Country World Investable Market Index (MSCI ACWI IMI). The Net-Zero Tracker will bring new levels of transparency to investors and policymakers regarding listed companies’ action on climate, providing aggregate progress on temperature alignment as well as highlighting industry leaders and laggards. The latest report shows that:
- A number of well-known publicly listed companies reported their indirect (i.e, Scope 3) emissions for the first time, including, Airbus SE, Baidu, Inc., and British American Tobacco plc, but not all the disclosures are comprehensive
- Westpac Banking Corporation and Booking Holdings Inc., the operator of Booking.com, KAYAK and OpenTable, reported only a small proportion of their total direct and indirect emissions
- The Procter & Gamble Company and ASML Holding N.V. both reported additional scopes in the previous quarter, to now report all company emissions across most of the relevant categories (i.e, Scope 1, 2 and 3)
- Coal India Limited was the largest emitter not to report any of its greenhouse gas emissions
Remy Briand, Global Head of ESG and Climate at MSCI, adds: “The MSCI Net-Zero Tracker is bringing a new level of transparency to the climate debate. It will allow investors to monitor whether listed companies have credible plans to reduce their carbon footprint and track the alignment of their own portfolios with the 2015 Paris Agreement. The data in our inaugural Net-Zero Tracker shows the need for a dramatic acceleration in action from the world’s public companies. For those not matching their commitments or lagging, there should be nowhere left to hide.”
About MSCI Inc.
MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data, and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process.
Notes to Editors
*Gigaton is equal to a billion tons
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or performance and involve risks that may cause actual results or performance differ materially and you should not place undue reliance on them. Risks that could affect results or performance are in MSCI’s Annual Report on Form 10-K for the most recent fiscal year ended on December 31 that is filed with the SEC. MSCI does not undertake to update any forward-looking statements. No information herein constitutes investment advice or should be relied on as such. MSCI grants no right or license to use its products or services without an appropriate license. MSCI MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR OTHERWISE WITH RESPECT TO THE INFORMATION HEREIN AND DISCLAIMS ALL LIABILITY TO THE MAXIMUM EXTENT PERMITTED BY LAW.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210712005532/en/
Contact information
Media Inquiries
PR@msci.com
Sam Wang +1 212 804 5244
Melanie Blanco +1 212 981 1049
Laura Hudson +44 (0) 207 336 9653
Rachel Lai +852 2844 9315
MSCI Global Client Services
EMEA Client Service + 44 20 7618.2222
Americas Client Service +1 888 588 4567 (toll free)
Asia Pacific Client Service + 852 2844 9333
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 15:29:00 EEST | Press release
Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level
Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
